BioRestorative Therapies
Open
$0.23
Prev. Close
$0.23
High
$0.23
Low
$0.22
Market Snapshot
$1.79M
-0.1
-1.16
$401K
14
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.
emptyResult
BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. The company is headquartered in Melville, New York and currently employs 11 full-time employees. The company went IPO on 2001-07-11. The firm has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The company has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The firm is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. The company also operates a commercial biocosmeceutical platform.
Recently from Cashu
It seems you haven't provided the content you'd like me to summarize. Please share the text, and I'll help you create a summary with a suitable title!
Please provide the text you would like me to summarize, and I'll be happy to create a summary for you.
Please provide the specific text or information about BioRestorative Therapies that you would like me to summarize.
To effectively summarize the content related to BioRestorative Therapies, please provide the specific text or information you wish to condense. Once you share that, I can create the requested article…
Please provide the content you would like summarized, and I'll help create a suitable title.
I'm sorry, but it appears I do not have the specific content you would like summarized. If you provide me with that text, I will gladly create an article summarizing it according to your guidelines.
Incomplete Press Materials Block AI Summaries, Risking Coverage for BioRestorative Therapies
Press-Readiness Gap Hinders Coverage of BioRestorative Therapies Missing source material halts summary of BioRestorative Therapies update An attempt to generate a 300‑word summary of recent material r…